Advanced searches left 3/3

Migraine - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

Healthy Living Partnerships for Veterans With Migraine

Veterans with migraine are more likely than those without headache to suffer medically related discharge/retirement, post-traumatic stress disorder, sleep disturbances, and difficulty reintegrating back into civilian life. Hence, finding alternate intervention strategies for migraine control is extremely valuable. This HELP-VM program assists veterans in taking charge of their own health and well-being, as well as the numerous health benefits of minimizing sedentary activity for migraine and beyond, which is consistent with the VA's Whole Health Initiative.

Source link: https://clinicaltrials.gov/ct2/show/NCT04373330


Enhancing the Efficacy of Migraine Self-Management in Children With Comorbid Insomnia

The purpose of this research is to determine whether changes in sleep can influence responses to CBT pain interventions, according to 1 test's effectiveness of cognitive-behavioral therapy CBT insomnia treatment for youth with migraine and comorbid insomnia. In Phase 2, all participants will have access to internet-delivered CBT pain therapy for over 6 weeks.

Source link: https://clinicaltrials.gov/ct2/show/NCT04936321


Efficacy of Memantine Compared With Sodium Valproate in the Prophylactic Treatment of Episodic Migraine.

When the headache occurs on fewer than 15 days a month, and chronic migraine when the migraine occurs on less than 15 days a month, and chronic migraine when the migraine occurs on more than 15 days a month, and at least eight days a month with the symptoms of migraine headache, the IHS also assigns a migraine. Migraine with aura and without aura are two of the migraine subtypes of migraine related to their clinical presentation, with visual signs being the most common. The pain phase in migraine is due to the activation and sensitization of the trigeminovascular pain pathway, which innervates intracranial organs, including the eye, the dura mater, large braincases, and the venous sinuses. A. Headache episodes are expected to last 72 hours, and they must comply with the IHS International Classification of Headaches' conditions, which are for migraine without aura. The migraine prevention and lifestyle changes go hand in hand with the pharmaceutical one; one would avoid the migraine attacks' triggers and carry out the lifestyle changes. Valproic acid was first synthesized in 1882 as an analog of valeric acid, which is also present in valerian. In clinical terms, two different research trials for sodium valproate showed a significant decrease in headache frequency than placebo, which shows us in clinical terms an approximate decrease of four headaches per every 28 days. paraphrasedoutput:Sodium valproate, according to Jensen 199413, is superior to placebo, meaning that patients are three times more likely to experience a drop equal to or higher than 50% in the frequency of headaches compared to placebo. Other studies support its assertion by revealing elevated glutamate levels in the cerebrospinal fluid in patients with chronic migraine in the ictal period and elevated serum levels in migraine patients. 15. In 2008, Bigal and colleagues conducted the first open clinical trial, a pilot study to compare memantine's effectiveness and safety as a prophylactic therapy in patients diagnosed with refractory migraine. A random sample of 52 patients, 25 with memantine and 27 with placebo, took place in 2015. Noruzzadeh and colleagues conducted the first controlled, double-blind, placebo-controlled clinical trial to determine memantine's effectiveness as a prophylactic treatment of migraine without aura in 2015, with a population of migraines without aura.

Source link: https://clinicaltrials.gov/ct2/show/NCT04698525


Effect of a Home-based Versus Supervised Exercise Program in Patients With Migraine: a Randomized Clinical Trial

This report will determine the effectiveness of home versus controlled exercise regimens in migraine patients. Changes in the Visual Analog Scale and Migraine Disability Assessment Scores will be the key findings. If you are between 18 and 55 years old, are of either sex, have been diagnosed with migraine, have been diagnosed with migraine, and have attended at least three days of migraine attacks in the last month, you will be randomly divided into two categories. In comparison to the control group's baseline group, the experimental group will run a controlled exercises program twice a week and then implement a home-based exercise program twice a week.

Source link: https://clinicaltrials.gov/ct2/show/NCT05292599


A Phase 1b, Open-label, Fixed-sequence, Safety, Tolerability and Drug-drug Interaction Study Between Atogepant and Ubrogepant in Participants With a History of Migraine

Migraine is a common medical disorder that is often associated with throbbing, moderate to severe headache, frequent with nausea, vomiting, and eyesight and sound, according to the patient. This research will investigate the drug-to-drug interaction between atogepant and ubrogepant, as well as the safety of atogepant and ubrogepant, whether used alone or in combination in adult migraine sufferers. Ubrogepant, a drug that has been approved for acute migraine treatment, is a drug approved for acute migraine relief. Participants will be given oral tablets of ubrogepant, oral tablets of atogepant, and the administration of oral tablets of atogepant and ubrogepant in combination.

Source link: https://clinicaltrials.gov/ct2/show/NCT04818515


A Multinational, Multi-centre, Randomised, Double-blind, Placebo-controlled, 3-way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo

Migraine headache affects 10% of the world population and has been classified by the World Health Organisation as one of the top 20 causes of disabling disorders and in the top four neurological disabling disorders. BGC20-1531 is an orally available EP4 receptor antagonist that reduces prostaglandin-induced sodilation of cranial blood vessels by a selective blockade of EP4 receptors reducing inflammation and migraine pain. EP4 receptor antagonists' overall safety profile may be enhanced compared to triptans and NSAIDs, as EP4 receptor receptors are discretely localised.

Source link: https://clinicaltrials.gov/ct2/show/NCT00888680

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions